Subbiah, V., Sen, S., Hess, K. R., Janku, F., Hong, D. S., Khatua, S., . . . Meric-Bernstam, F. (2018). Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol.
Citação norma ChicagoSubbiah, Vivek, et al. "Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies." JCO Precis Oncol 2018.
MLA citiranjeSubbiah, Vivek, et al. "Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies." JCO Precis Oncol 2018.